Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/103216
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Author: Weber, N.
Mollee, P.
Augustson, B.
Brown, R.
Catley, L.
Gibson, J.
Harrison, S.
Ho, P.
Horvath, N.
Jaksic, W.
Joshua, D.
Quach, H.
Roberts, A.
Spencer, A.
Szer, J.
Talaulikar, D.
To, B.
Zannettino, A.
Prince, H.
Citation: Internal Medicine Journal, 2015; 45(4):371-382
Publisher: Wiley
Issue Date: 2015
ISSN: 1444-0903
1445-5994
Statement of
Responsibility: 
N. Weber, P. Mollee, B. Augustson, R. Brown, L. Catley, J. Gibson, S. Harrison, P. J. Ho, N. Horvath, W. Jaksic, D. Joshua, H. Quach, A. W. Roberts, A. Spencer, J. Szer, D. Talaulikar, B. To, A. Zannettino and H. M. Prince
Abstract: Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein. This condition poses a unique management challenge due to the complexity of the clinical presentation and the narrow therapeutic window of available therapies. Improved appreciation of the need for risk stratification, standardised use of sensitive laboratory testing for monitoring disease response, vigilant supportive care and the availability of newer agents with more favourable toxicity profiles have contributed to the improvement in treatment-related mortality and overall survival seen over the past decade. Nonetheless, with respect to the optimal management approach, there is a paucity of high-level clinical evidence due to the rarity of the disease, and enrolment in clinical trials is still the preferred approach where available. This review will summarise the Clinical Practice Guidelines on the Management of Systemic Light Chain (AL) Amyloidosis recently prepared by the Medical Scientific Advisory Group of the Myeloma Foundation of Australia. It is hoped that these guidelines will assist clinicians in better understanding and optimising the management of this difficult disease.
Keywords: amyloidosis; light chain; AL, plasma cell
Rights: © 2014 Royal Australasian College of Physicians
RMID: 0030036119
DOI: 10.1111/imj.12566
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.